Treatment outcomes of ureteral stenting for malignant extrinsic ureteral obstruction: a comparison between polymeric and metallic stents

Figures & data

Table 1 Patient characteristics

	All patients (N=92)		Polymeric (N=35)		Metallic (N=57)		p-value
Total number of ureters	126		54		72
Age (median) (years)	66	(24–90)	64	(35–80)	68	(24–90)	0.176
Sex	Male: 39	Female: 53	Male: 11	Female: 24	Male: 27	Female: 45	0.538
Observation period (median) (days)	145	(1–365)	178	(2–365)	163	(2–365)	0.244
Primary disease							0.002
Gastrointestinal cancer	50		13		37
Gynecological cancer	31		20		11
Urogenital cancer	4		0		4
Other	7		2		5
Obstructed side	Unilateral 58	Bilateral 34	Unilateral 16	Bilateral 19	Unilateral 42	Bilateral 15	0.007
Cause of ureteral obstruction							0.111
Direct compression by tumor	30		11		19
Lymph node metastasis	26		14		12
Abdominal dissemination	36		10		26

Figure 1 Median survival time of the 92 patients with MUO.

Abbreviation: MUO, malignant ureteral obstruction.

Figure 2 Stent patency rate for MUO.

Abbreviation: MUO, malignant ureteral obstruction.

Table 2 Results of the Cox proportional stepwise multivariate analysis of the association between the variables and stent failure

Comparison	Unadjusted				Adjusted
	HR	95% CI		p-value	HR	95% CI		p-value
Cause of obstruction
Dissemination vs other	1.240	0.609	2.523	0.553
Lymph node vs other	1.156	0.537	2.488	0.711
Tumor vs other	0.691	0.339	1.404	0.307
Stent type
Polymeric vs metallic	2.153	1.070	4.230	0.031	2.032	0.980	4.210	0.057

Figure 3 Patency rate for the 2 stent types.